Purpose: The systemic treatment of cancer is primarily through the administration of complex chemotherapy protocols. To date, this knowledge has not been systematized, because of the lack of a consistent nomenclature and the variation in which regimens are documented. For example, recording of treatment events in electronic health record notes is often through shorthand and acronyms, limiting secondary use. A standardized hierarchic ontology of cancer treatments, mapped to standard nomenclatures, would be valuable to a variety of end users. Methods: We leveraged the knowledge contained in a large wiki of hematology/oncology drugs and treatment regimens, HemOnc.org. Through algorithmic parsing, we created a hierarchic ontology of treatment concepts in the World Wide Web Consortium Web Ontology Language. We also mapped drug names to RxNorm codes and created optional filters to restrict the ontology by disease and/or drug class. Results: As of December 2017, the main ontology includes 30,526 axioms (eg, doxorubicin is an anthracycline), 1,196 classes (eg, regimens used in the neoadjuvant treatment of human epidermal growth factor receptor 2-positive breast cancer, nitrogen mustards), and 1,728 individual entities. More than 13,000 of the axioms are annotations including RxNorm codes, drug synonyms, literature references, and direct links to published articles. Conclusion: This approach represents, to our knowledge, the largest effort to date to systematically categorize and relate hematology/oncology drugs and regimens. The ontology can be used to reason individual components from regimens mentioned in electronic health records (eg, R-CHOP maps to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) and also to probabilistically reconstruct regimens from individual drug components. These capabilities may be particularly valuable in the implementation of rapid-learning health systems on the basis of real-world evidence. The derived Web Ontology Language ontology is freely available for noncommercial use through the Creative Commons 4.0 Attribution-NonCommercial-ShareAlike license.
Purpose: The systemic treatment of cancer is primarily through the administration of complex chemotherapy protocols. To date, this knowledge has not been systematized, because of the lack of a consistent nomenclature and the variation in which regimens are documented. For example, recording of treatment events in electronic health record notes is often through shorthand and acronyms, limiting secondary use. A standardized hierarchic ontology of cancer treatments, mapped to standard nomenclatures, would be valuable to a variety of end users. Methods: We leveraged the knowledge contained in a large wiki of hematology/oncology drugs and treatment regimens, HemOnc.org. Through algorithmic parsing, we created a hierarchic ontology of treatment concepts in the World Wide Web Consortium Web Ontology Language. We also mapped drug names to RxNorm codes and created optional filters to restrict the ontology by disease and/or drug class. Results: As of December 2017, the main ontology includes 30,526 axioms (eg, doxorubicin is an anthracycline), 1,196 classes (eg, regimens used in the neoadjuvant treatment of humanepidermal growth factor receptor 2-positive breast cancer, nitrogen mustards), and 1,728 individual entities. More than 13,000 of the axioms are annotations including RxNorm codes, drug synonyms, literature references, and direct links to published articles. Conclusion: This approach represents, to our knowledge, the largest effort to date to systematically categorize and relate hematology/oncology drugs and regimens. The ontology can be used to reason individual components from regimens mentioned in electronic health records (eg, R-CHOP maps to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) and also to probabilistically reconstruct regimens from individual drug components. These capabilities may be particularly valuable in the implementation of rapid-learning health systems on the basis of real-world evidence. The derived Web Ontology Language ontology is freely available for noncommercial use through the Creative Commons 4.0 Attribution-NonCommercial-ShareAlike license.
Authors: Guergana K Savova; Eugene Tseytlin; Sean Finan; Melissa Castine; Timothy Miller; Olga Medvedeva; David Harris; Harry Hochheiser; Chen Lin; Girish Chavan; Rebecca S Jacobson Journal: Cancer Res Date: 2017-11-01 Impact factor: 12.701
Authors: Volker Heinemann; Detlef Quietzsch; Frank Gieseler; Michael Gonnermann; Herbert Schönekäs; Andreas Rost; Horst Neuhaus; Caroline Haag; Michael Clemens; Bernard Heinrich; Ursula Vehling-Kaiser; Martin Fuchs; Doris Fleckenstein; Wolfgang Gesierich; Dirk Uthgenannt; Hermann Einsele; Axel Holstege; Axel Hinke; Andreas Schalhorn; Ralf Wilkowski Journal: J Clin Oncol Date: 2006-08-20 Impact factor: 44.544
Authors: Giuseppe Colucci; Roberto Labianca; Francesco Di Costanzo; Vittorio Gebbia; Giacomo Cartenì; Bruno Massidda; Elisa Dapretto; Luigi Manzione; Elena Piazza; Mirella Sannicolò; Marco Ciaparrone; Luigi Cavanna; Francesco Giuliani; Evaristo Maiello; Antonio Testa; Paolo Pederzoli; Massimo Falconi; Ciro Gallo; Massimo Di Maio; Francesco Perrone Journal: J Clin Oncol Date: 2010-03-01 Impact factor: 44.544
Authors: Michael A Fridrik; Ulrich Jaeger; Andreas Petzer; Wolfgang Willenbacher; Felix Keil; Alois Lang; Johannes Andel; Sonja Burgstaller; Otto Krieger; Willi Oberaigner; Kurt Sihorsch; Richard Greil Journal: Eur J Cancer Date: 2016-03-15 Impact factor: 9.162
Authors: A T Skarin; G P Canellos; D S Rosenthal; D C Case; J M MacIntyre; G S Pinkus; W C Moloney; E Frei Journal: J Clin Oncol Date: 1983-02 Impact factor: 44.544
Authors: Jona Kräenbring; Tika Monzon Penza; Joanna Gutmann; Susanne Muehlich; Oliver Zolk; Leszek Wojnowski; Renke Maas; Stefan Engelhardt; Antonio Sarikas Journal: PLoS One Date: 2014-09-24 Impact factor: 3.240
Authors: Jeremy L Warner; Dmitry Dymshyts; Christian G Reich; Michael J Gurley; Harry Hochheiser; Zachary H Moldwin; Rimma Belenkaya; Andrew E Williams; Peter C Yang Journal: J Biomed Inform Date: 2019-06-22 Impact factor: 6.317
Authors: Julie Wu; Jordan Bryan; Samuel M Rubinstein; Lucy Wang; Michele Lenoue-Newton; Raed Zuhour; Mia Levy; Christine Micheel; Yaomin Xu; Suresh K Bhavnani; Lester Mackey; Jeremy L Warner Journal: JCO Precis Oncol Date: 2020-06-25
Authors: Samuel M Rubinstein; Tarsheen Sethi; Neeta K Venepalli; Bishal Gyawali; Candice Schwartz; Donna R Rivera; Peter C Yang; Jeremy L Warner Journal: JCO Clin Cancer Inform Date: 2021-01
Authors: Fernando Suarez Saiz; Corey Sanders; Rick Stevens; Robert Nielsen; Michael Britt; Leemor Yuravlivker; Anita M Preininger; Gretchen P Jackson Journal: JCO Clin Cancer Inform Date: 2021-01
Authors: Kim M Unertl; Braden Y Yang; Rischelle Jenkins; Claudia McCarn; Courtney Rabb; Kevin B Johnson; Cynthia S Gadd Journal: JAMIA Open Date: 2018-07-30
Authors: Samuel M Rubinstein; Elizabeth A Sigworth; Shervin Etemad; Richard L Martin; Qingxia Chen; Jeremy L Warner Journal: JAMA Netw Open Date: 2019-12-02